Partnerships that connect internal and external resources

「神経再生誘導材 ReFeelⓇについて、米国の PBC Biomed Inc.（米国・テネシー州メンフィス、President：Paul Burke）と米国における販売提携契約を締結しましたので、お知らせします。」

「In October 2025, we entered into a basic business partnership agreement with AUSPICIOUS株式会社 concerning medical device products in the orthopaedics field. In December 2025, we entered into an agreement with Canada's Duchesnay Inc. concerning the development and marketing in Japan of Bonjesta, a treatment for nausea and vomiting during pregnancy, commonly known as morning sickness. In March 2026, we entered into an agreement with LG Chem, Ltd. of South Korea concerning the marketing in South Korea and Thailand of dienogest, which we market in Japan for endometriosis and other indications. In addition, in March 2026, we entered into an agreement with China's Qilu Pharmaceutical Co., Ltd. concerning the development and marketing in Japan of a biosimilar of follitropin alfa (genetically recombined), which is used in infertility treatment.」

「On 22 September 2025, we entered into an agreement concerning the underwriting of a third-party allotment of shares by アンドファーマ株式会社 and the acquisition of shares in アンドファーマ株式会社 by acquiring part of the shares held by 合同会社ジェイ・イー・エイチ. As a result, we acquired a 20% stake in アンドファーマ株式会社 effective 1 October 2025 and made the company an equity-method associate.」

「In August 2024, we entered into an agreement with Meiji Seika Pharma Co., Ltd. concerning the marketing of Epadel in the ASEAN region and Taiwan. In October 2024, we entered into an agreement with United Therapeutics Corporation of the United States concerning the domestic marketing rights for TYVASO DPI, a treatment for pulmonary hypertension. In December 2024, we entered into an agreement with Korea's Kuhnil Pharm. Co., Ltd. concerning the marketing of Epadel in South Korea. In March 2025, we entered into a joint commercialization agreement with S-Quatre Co., Ltd. for SHED, dental pulp stem cells from exfoliated deciduous teeth, for pediatric cerebral palsy and traumatic brain injury.」

「The Group conducts R&D activities focused primarily on prescription drugs, putting into practice its corporate creed of “foresight, originality and research” and actively pursuing R&D partnerships with companies in Japan and overseas.」

「In addition, in October 2023, we entered into a marketing partnership agreement with Shionogi & Co.,Ltd. for ACT-541468 in Japan. In March 2024, we also entered into an agreement with Meiji Seika Pharma Co., Ltd. concerning the marketing of MND-21 in China.」

「The following important sales agreement was newly executed during the third quarter of the fiscal year. Counterparty: Shionogi & Co., Ltd. Country: Japan Contract: Supply and exclusive distribution of the insomnia treatment “ACT-541468” Contract year: 2023」

「The Group conducts R&D activities focused primarily on prescription drugs, putting into practice its corporate creed of “foresight, originality and research” and actively pursuing R&D partnerships with companies in Japan and overseas.」

「Following the additional acquisition of shares in PuREC Co., Ltd., the company included PuREC Co., Ltd. within the scope of application of the equity method.」

「In the field of regenerative medicine products, the company made investments for the future, including by entering into a business partnership agreement with PuREC Co., Ltd. covering the development of manufacturing processes for high-purity mesenchymal stem cell REC and related matters, and a joint commercialization agreement with Human Life Code Co., Ltd. for the umbilical-cord-derived cell therapy product “HLC-001.”」

「As part of its licensing activities, the company entered into agreements in December 2022 with Ferring Pharmaceuticals Co., Ltd. and Eli Lilly Japan K.K., respectively, for therapeutic products indicated for ulcerative colitis.」

「The Group conducts R&D activities focused primarily on prescription drugs, putting into practice its corporate creed of “foresight, originality and research” and actively pursuing R&D partnerships with companies in Japan and overseas.」

「The Group conducts R&D activities focused primarily on prescription drugs, putting into practice its corporate creed of “foresight, originality and research” and actively pursuing R&D partnerships with companies in Japan and overseas.」

「The Group conducts R&D activities focused primarily on prescription drugs, putting into practice its corporate creed of “foresight, originality and research” and actively pursuing R&D partnerships with companies in Japan and overseas.」

「For “Epadel,” the overseas subsidiary of the partner obtained import and marketing approval in Thailand in October 2020 for the indication of hypertriglyceridemia and began sales in April 2021. In Vietnam, the partner’s affiliated partner applied for import and marketing approval.」

「In March 2020, the company entered into a joint commercialization agreement with GeneTechno Science Co., Ltd. covering regenerative medicine products for rare and intractable diseases in the gastrointestinal field, including intestinal neuronal dysplasia. In March 2020, it also entered into an agreement with Meiji Seika Pharma Co., Ltd. for the sale of “Epadel” in Vietnam.」

「During the first three months of the fiscal year, the company entered into a memorandum of understanding with Mitsubishi Tanabe Pharma Corporation regarding an extension of the term and other matters under the agreement for the co-promotion of the antidepressant “Lexapro.”」

「The pediatric indication for “Lexapro” and the antidepressant “desvenlafaxine (generic name),” for which the company entered into an agreement with Pfizer Inc. in March 2019 covering development, sales and other matters, are each in Phase III clinical development.」

「In June 2018, the company entered into an agreement with Amarin Corporation for the development and commercialization of a novel high-purity EPA formulation in the United States and other regions.」

「In addition, the company entered into an agreement with Janssen Pharmaceutical K.K., the marketing authorization holder for the oncology drug “Doxil,” to sell the drug in Japan, and has been selling it since January 2018. The company also entered into an agreement with Meiji Seika Pharma Co., Ltd. for the sale of “Epadel” in Thailand.」

「The company entered into an agreement with Meiji Seika Pharma Co., Ltd. for the sale of “Epadel” in Thailand. It also entered into an agreement with Janssen Pharmaceutical K.K., the marketing authorization holder for the oncology drug “Doxil,” under which the company would sell the drug in Japan from 1 January 2018.」

「The company will prioritize partnerships with external parties, link internal and external resources, further strengthen its areas of strength, and complement its weaker areas.」